Animal Models of Human Pathology

Eosinophils in Health and Disease

Volumn , Issue , 2013, Pages 537-575

  Lee, James J ^a   Blanchard, Carine ^b   Masterson, Joanne C ^c,d   Furuta, Glenn T ^c,d   Waddell, Amanda ^e   Hogan, Simon P ^e   Yamada, Yoshiyuki ^f   Cancelas, Jose A ^g   Rothenberg, Marc E ^g  

^a MAYO CLINIC   (United States)

^b NESTLÉ RESEARCH CENTER   (Switzerland)

^c Children's Hospital   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CINCINNATI   (United States)

^f Gunma Children's Medical Center   (Japan)

^g UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^h Wole) Odemuyiwa S O   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882825034     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-394385-9.00014-6     Document Type: Chapter

References (232)

1. Tomassini M., Tsicopoulos A., Tai P.C., Gruart V., Tonnel A.B., Prin L., et al. Release of granule proteins by eosinophils from allergic and nonallergic patients with eosinophilia on immunoglobulin-dependent activation. Journal of Allergy & Clinical Immunology 1991, 88(3 Pt 1):365-375.
2. Bousquet J., Chanez P., Lacoste J.Y., Barneon G., Ghavanian N., Enander I., et al. Eosinophilic inflammation in asthma [see comments]. New England Journal of Medicine 1990, 323(15):1033-1039.
3. Huber H.L., Koessler K.K. The Pathology of Bronchial Asthma. Archives of Internal Medicine 1922, 30(6):689-760.
4. Stelmach I., Majak P., Grzelewski T., Jerzynska J., Juralowicz D., Stelmach W., et al. The ECP/Eo count ratio in children with asthma. J Asthma 2004, 41(5):539-546.
5. Nair P., Pizzichini M.M., Kjarsgaard M., Inman M.D., Efthimiadis A., Pizzichini E., et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009, 360(10):985-993.
6. Robinson D.S., Assoufi B., Durham S.R., Kay A.B. Eosinophil cationic protein (ECP) and eosinophil protein X (EPX) concentrations in serum and bronchial lavage fluid in asthma. Effect of prednisolone treatment. Clin Exp Allergy 1995, 25(11):1118-1127.
7. Foster P.S., Hogan S.P., Ramsay A.J., Matthaei K.I., Young I.G. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model [see comments]. J Exp Med 1996, 183(1):195-201.
8. Hogan S.P., Matthaei K.I., Young J.M., Koskinen A., Young I.G., Foster P.S. A novel T cell-regulated mechanism modulating allergen-induced airways hyperreactivity in BALB/c mice independently of IL-4 and IL-5. Journal of Immunology 1998, 161(3):1501-1509.
9. Kuperman D.A., Lewis C.C., Woodruff P.G., Rodriguez M.W., Yang Y.H., Dolganov G.M., et al. Dissecting asthma using focused transgenic modeling and functional genomics. J Allergy Clin Immunol 2005, 116(2):305-311.
10. Epstein M.M. Do mouse models of allergic asthma mimic clinical disease?. Int Arch Allergy Immunol 2004, 133(1):84-100.
11. Waterston R.H., Lindblad-Toh K., Birney E., Rogers J., Abril J.F., Agarwal P., et al. Initial sequencing and comparative analysis of the mouse genome. Nature 2002, 420(6915):520-562.
12. Kung T.T., Stelts D.M., Zurcher J.A., Adams G.K., Egan R.W., Kreutner W., et al. Involvement of IL-5 in a murine model of allergic pulmonary inflammation-prophylactic and therapeutic effect of an anti-IL-5 antibody. Am J Respir Cell Mol Biol 1995, 13(3):360-365.
13. Egan R.W., Athwahl D., Chou C.C., Chapman R.W., Emtage S., Jenh C.H., et al. Pulmonary biology of anti-interleukin 5 antibodies. Mem Inst Oswaldo Cruz 1997, 92(Suppl. 2):69-73.
14. Garlisi C.G., Kung T.T., Wang P., Minnicozzi M., Umland S.P., Chapman R.W., et al. Effects of chronic anti-interleukin-5 monoclonal antibody treatment in a murine model of pulmonary inflammation. Am J Respir Cell Mol Biol 1999, 20(2):248-255.
15. Leckie M.J., ten Brinke A., Khan J., Diamant Z., O'Connor B.J., Walls C.M., et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000, 356(9248):2144-2148.
16. Kips J.C., Anderson G.P., Fredberg J.J., Herz U., Inman M.D., Jordana M., et al. Murine models of asthma. Eur Respir J 2003, 22(2):374-382.
17. Erlich P. Ueber die Specifischen granulationen des Blutes [in German]. Arch Anant Physiol 1879, 3:571-579.
18. O'Byrne P.,M., Inman M.D., Parameswaran K. The trials and tribulations of IL-5, eosinophils, and allergic asthma. J Allergy Clin Immunol 2001, 108(4):503-508.
19. Haldar P., Brightling C.E., Hargadon B., Gupta S., Monteiro W., Sousa A., et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009, 360(10):973-984.
20. Lee N.A., Gelfand E.W., Lee J.J. Pulmonary T cells and eosinophils: coconspirators or independent triggers of allergic respiratory pathology?. Journal of Allergy and Clinical Immunology 2001, 107(6):945-957.
21. Lee J.J., Dimina D., Macias M.P., Ochkur S.I., McGarry M.P., O'Neill K.R., et al. Defining a link with asthma in mice congenitally deficient in eosinophils. Science 2004, 305(5691):1773-1776.
22. Henderson W., Chi E.Y., Albert R.K., Chu S.J., Lamm W.J.E., Rochon Y., et al. Blockade of CD49D (alpha(4) integrin) on intrapulmonary but not circulating leukocytes inhibits airway inflammation and hyperresponsiveness in a mouse model of asthma. Journal of Clinical Investigation 1997, 100(12):3083.
23. Hamelmann E., Cieslewicz G., Schwarze J., Ishizuka T., Joetham A., Heusser C., et al. Anti-interleukin 5 but not anti-IgE prevents airway inflammation and airway hyperresponsiveness. Am J Respir Crit Care Med 1999, 160(3):934-941.
24. Shen H.H., Ochkur S.I., McGarry M.P., Crosby J.R., Hines E.M., Borchers M.T., et al. A causative relationship exists between eosinophils and the development of allergic pulmonary pathologies in the mouse. J Immunol 2003, 170:3296-3305.
25. Flood-Page P.T., Menzies-Gow A.N., Kay A.B., Robinson D.S. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003, 167(2):199-204.
26. Humbles A.A., Lu B., Friend D.S., Okinaga S., Lora J., Al-Garawi A., et al. The murine CCR3 receptor regulates both the role of eosinophils and mast cells in allergen-induced airway inflammation and hyperresponsiveness. Proc Natl Acad Sci USA 2002, 99(3):1479-1484.
27. Ma W., Bryce P.J., Humbles A.A., Laouini D., Yalcindag A., Alenius H., et al. CCR3 is essential for skin eosinophilia and airway hyperresponsiveness in a murine model of allergic skin inflammation. J Clin Invest 2002, 109(5):621-628.
28. Mattes J., Yang M., Mahalingam S., Kuehr J., Webb D.C., Simson L., et al. Intrinsic defect in T cell production of interleukin (IL)-13 in the absence of both IL-5 and eotaxin precludes the development of eosinophilia and airways hyperreactivity in experimental asthma. J Exp Med 2002, 195(11):1433-1444.
29. Humbles A.A., Lloyd C.M., McMillan S.J., Friend D.S., Xanthou G., McKenna E.E., et al. A critical role for eosinophils in allergic airways remodeling. Science 2004, 305(5691):1776-1779.
30. Walsh E.R., Sahu N., Kearley J., Benjamin E., Kang B.H., Humbles A., et al. Strain-specific requirement for eosinophils in the recruitment of T cells to the lung during the development of allergic asthma. J Exp Med 2008, 205(6):1285-1292.
31. de Bruin A.M., Buitenhuis M., van der Sluijs K.F., van Gisbergen K.P., Boon L., Nolte M.A. Eosinophil differentiation in the bone marrow is inhibited by T cell-derived IFN-gamma. Blood 2010, 116(14):2559-2569.
32. Cho J.Y., Miller M., Baek K.J., Han J.W., Nayar J., Lee S.Y., et al. Inhibition of airway remodeling in IL-5-deficient mice. J Clin Invest 2004, 113(4):551-560.
33. Lee N.A., McGarry M.P., Larson K.A., Horton M.A., Kristensen A.B., Lee J.J. Expression of IL-5 in thymocytes/T cells leads to the development of a massive eosinophilia, extramedullary eosinophilopoiesis, and unique histopathologies. J Immunol 1997, 158(3):1332-1344.
34. Lee J.J., McGarry M.P., Farmer S.C., Denzler K.L., Larson K.A., Carrigan P.E., et al. Interleukin-5 expression in the lung epithelium of transgenic mice leads to pulmonary changes pathognomonic of asthma. Journal of Experimental Medicine 1997, 185(12):2143-2156.
35. Ochkur S.I., Jacobsen E.A., Protheroe C.A., Biechele T.L., Pero R.S., McGarry M.P., et al. Co-Expression of IL-5 and Eotaxin-2 in Mice Creates an Eosinophil-Dependent Model of Respiratory Inflammation with Characteristics of Severe Asthma. Journal of Immunology 2007, 178(12):7879-7889.
36. Kips J.C., O'Connor B.J., Langley S.J., Woodcock A., Kerstjens H.A., Postma D.S., et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2003, 167(12):1655-1659.
37. Wills-Karp M., Karp C.L. Biomedicine. Eosinophils in asthma: remodeling a tangled tale. Science 2004, 305(5691):1726-1729.
38. Persson C.G., Erjefalt J.S., Korsgren M., Sundler F. The mouse trap. Trends Pharmacol Sci 1997, 18(12):465-467.
39. Justice J.P., Borchers M.T., Crosby J.R., Hines E.M., Shen H.H., Ochkur S.I., et al. Ablation of eosinophils leads to a reduction of allergen-induced pulmonary pathology. Am J Physiol Lung Cell Mol Physiol 2003, 284(1):L169-L178.
40. Pope S.M., Zimmermann N., Stringer K.F., Karow M.L., Rothenberg M.E. The Eotaxin Chemokines and CCR3 are Fundamental Regulators of Allergen-Induced Pulmonary Eosinophilia. J Immunol 2005, 175(8):5341-5350.
41. Fulkerson P.C., Fischetti C.A., McBride M.L., Hassman L.M., Hogan S.P., Rothenberg M.E. A central regulatory role for eosinophils and the eotaxin/CCR3 axis in chronic experimental allergic airway inflammation. Proc Natl Acad Sci USA 2006, 103(44):16418-16423.
42. Mehlhop P.D., van de Rijn M., Goldberg A.B., Brewer J.P., Kurup V.P., Martin T.R., et al. Allergen-induced bronchial hyperreactivity and eosinophilic inflammation occur in the absence of IgE in a mouse model of asthma. Proc Natl Acad Sci USA 1997, 94:1344-1349.
43. Mishra A., Hogan S.P., Brandt E.B., Rothenberg M.E. An etiological role for aeroallergens and eosinophils in experimental esophagitis. J Clin Invest 2001, 107:83-90.
44. Zhu X., Wang M., Crump C.H., Mishra A. An imbalance of esophageal effector and regulatory T cell subsets in experimental eosinophilic esophagitis in mice. Am J Physiol Gastrointest Liver Physiol 2009, 297:G550-G558.
45. Zhu X., Wang M., Mavi P., Rayapudi M., Pandey A.K., Kaul A., et al. Interleukin-15 expression is increased in human eosinophilic esophagitis and mediates pathogenesis in mice. Gastroenterology 2010, 139:182-193.
46. Rayapudi M., Mavi P., Zhu X., Pandey A.K., Abonia J.P., Rothenberg M.E., et al. Indoor insect allergens are potent inducers of experimental eosinophilic esophagitis in mice. J Leukoc Biol 2010, 88:337-346.
47. Hogan S.P., Mishra A., Brandt E.B., Royalty M.P., Pope S.M., Zimmermann N., et al. A pathological function for eotaxin and eosinophils in eosinophilic gastrointestinal inflammation. Nat Immunol 2001, 2:353-360.
48. Akei H.S., Brandt E.B., Mishra A., Strait R.T., Finkelman F.D., Warrier M.R., et al. Epicutaneous aeroallergen exposure induces systemic TH2 immunity that predisposes to allergic nasal responses. J Allergy Clin Immunol 2006, 118:62-69.
49. Akei H.S., Mishra A., Blanchard C., Rothenberg M.E. Epicutaneous antigen exposure primes for experimental eosinophilic esophagitis in mice. Gastroenterology 2005, 129:985-994.
50. Noel R.J., Putnam P.E., Rothenberg M.E. Eosinophilic esophagitis. N Engl J Med 2004, 351:940-941.
51. Wang F.Y., Gupta S.K., Fitzgerald J.F. Is there a seasonal variation in the incidence or intensity of allergic eosinophilic esophagitis in newly diagnosed children?. J Clin Gastroenterol 2007, 41:451-453.
52. Almansa C., Krishna M., Buchner A.M., Ghabril M.S., Talley N., DeVault K.R., et al. Seasonal distribution in newly diagnosed cases of eosinophilic esophagitis in adults. Am J Gastroenterol 2009, 104:828-833.
53. Mishra A., Rothenberg M.E. Intratracheal IL-13 induces eosinophilic esophagitis by an IL-5, eotaxin-1, and STAT6-dependent mechanism. Gastroenterology 2003, 125:1419-1427.
54. Blanchard C., Mishra A., Saito-Akei H., Monk P., Anderson I., Rothenberg M.E. Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354). Clin Exp Allergy 2005, 35:1096-1103.
55. Mishra A., Hogan S.P., Brandt E.B., Rothenberg M.E. IL-5 promotes eosinophil trafficking to the esophagus. J Immunol 2002, 168:2464-2469.
56. Zuo L., Fulkerson P.C., Finkelman F.D., Mingler M., Fischetti C.A., Blanchard C., et al. IL-13 induces esophageal remodeling and gene expression by an eosinophil-independent, IL-13R alpha 2-inhibited pathway. J Immunol 2010, 185:660-669.
57. Blanchard C., Wang N., Stringer K.F., Mishra A., Fulkerson P.C., Abonia J.P., et al. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest 2006, 116:536-547.
58. Milner J.D., Ward J.M., Keane-Myers A., Paul W.E. Lymphopenic mice reconstituted with limited repertoire T cells develop severe, multiorgan, Th2-associated inflammatory disease. Proc Natl Acad Sci USA 2007, 104:576-581.
59. Mazzei M.J., Bissett S.A., Murphy K.M., Hunter S., Neel J.A. Eosinophilic esophagitis in a dog. J Am Vet Med Assoc 2009, 235:61-65.
60. Gijbels M.J., Elliott G.R., HogenEsch H., Zurcher C., van den Hoven A., Bruijnzeel P.L. Therapeutic interventions in mice with chronic proliferative dermatitis (cpdm/cpdm). Exp Dermatol 2000, 9:351-358.
61. Gijbels M.J., HogenEsch H., Blauw B., Roholl P., Zurcher C. Ultrastructure of epidermis of mice with chronic proliferative dermatitis. Ultrastruct Pathol 1995, 19:107-111.
62. Mishra A., Wang M., Pemmaraju V.R., Collins M.H., Fulkerson P.C., Abonia J.P., et al. Esophageal remodeling develops as a consequence of tissue specific IL-5-induced eosinophilia. Gastroenterology 2008, 134:204-214.
63. Akei H.S., Brandt E.B., Mishra A., Strait R.T., Finkelman F.D., Warrier M.R., et al. Epicutaneous aeroallergen exposure induces systemic TH2 immunity that predisposes to allergic nasal responses. J Allergy Clin Immunol 2006, 118:62-69.
64. Blanchard C., Mingler M.K., McBride M., Putnam P.E., Collins M.H., Chang G., et al. Periostin facilitates eosinophil tissue infiltration in allergic lung and esophageal responses. Mucosal Immunol 2008, 1:289-296.
65. Mishra A., Schlotman J., Wang M., Rothenberg M.E. Critical role for adaptive T cell immunity in experimental eosinophilic esophagitis in mice. J Leukoc Biol 2007, 81:916-924.
66. Blanchard C., Mingler M.K., Vicario M., Abonia J.P., Wu Y.Y., Lu T.X., et al. IL-13 involvement in eosinophilic esophagitis: transcriptome analysis and reversibility with glucocorticoids. J Allergy Clin Immunol 2007, 120:1292-1300.
67. Pope S.M., Fulkerson P.C., Blanchard C., Akei H.S., Nikolaidis N.M., Zimmermann N., et al. Identification of a cooperative mechanism involving interleukin-13 and eotaxin-2 in experimental allergic lung inflammation. J Biol Chem 2005, 280:13952-13961.
68. Neilsen C.V., Bryce P.J. Interleukin-13 directly promotes oesophagus production of CCL11 and CCL24 and the migration of eosinophils. Clin Exp Allergy 2010, 40:427-434.
69. Aceves S.S., Ackerman S.J. Relationships between eosinophilic inflammation, tissue remodeling, and fibrosis in eosinophilic esophagitis. Immunol Allergy Clin North Am 2009, 29. 197-xiv.
70. Blanchard C., Stucke E.M., Burwinkel K., Caldwell J.M., Collins M.H., Ahrens A., et al. Coordinate interaction between IL-13 and epithelial differentiation cluster genes in eosinophilic esophagitis. J Immunol 2010, 184:4033-4041.
71. Blanchard C., Stucke E.M., Burwinkel K., Caldwell J.M., Collins M.H., Ahrens A., et al. Coordinate interaction between IL-13 and epithelial differentiation cluster genes in eosinophilic esophagitis. J Immunol 2010, 184:4033-4041.
72. Aceves S.S., Newbury R.O., Chen D., Mueller J., Dohil R., Hoffman H., et al. Resolution of remodeling in eosinophilic esophagitis correlates with epithelial response to topical corticosteroids. Allergy 2010, 65:109-116.
73. Sherrill J.D., Gao P.S., Stucke E.M., Blanchard C., Collins M.H., Putnam P.E., et al. Variants of thymic stromal lymphopoietin and its receptor associate with eosinophilic esophagitis. J Allergy Clin Immunol 2010, 126:160-165.
74. Rothenberg M.E., Spergel J.M., Sherrill J.D., Annaiah K., Martin L.J., Cianferoni A., et al. Common variants at 5q22 associate with pediatric eosinophilic esophagitis. Nat Genet 2010, 42:289-291.
75. Mondoulet L., Dioszeghy V., Larcher T., Ligouis M., Dhelft V., Puteaux E., et al. Epicutaneous immunotherapy (EPIT) blocks the allergic esophago-gastro-enteropathy induced by sustained oral exposure to peanuts in sensitized mice. PLoS One 2012, 7(2). e31967. Epub 2012 Feb 21.
76. Rajavelu P., Rayapudi M., Moffitt M., Mishra A., Mishra A. Significance of para-esophageal lymph nodes in food or aeroallergen-induced iNKT cell-mediated experimental eosinophilic esophagitis. Am J Physiol Gastrointest Liver Physiol 2012, 302(7):G645-G654. 2012 Apr.
77. Mavi P., Rajavelu P., Rayapudi M., Paul R.J., Mishra A. Esophageal functional impairments in experimental eosinophilic esophagitis. Am J Physiol Gastrointest Liver Physiol 2012 Feb 23, [Epub ahead of print].
78. Spergel J.M., Mizoguchi E., Brewer J.P., Martin T.R., Bhan A.K., Geha R.S. Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice. J Clin Invest 1998 Apr 15, 101(8):1614-1622.
79. Barrett J.C., Hansoul S., Nicolae D.L., Cho J.H., Duerr R.H., Rioux J.D., et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008, 40:955-962.
80. Fisher S.A., Tremelling M., Anderson C.A., Gwilliam R., Bumpstead S., Prescott N.J., et al. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nat Genet 2008, 40:710-712.
81. Silverberg M.S., Cho J.H., Rioux J.D., McGovern D.P., Wu J., Annese V., et al. Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nat Genet 2009, 41:216-220.
82. Frank D.N., St Amand A.L., Feldman R.A., Boedeker E.C., Harpaz N., Pace N.R. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 2007, 104:13780-13785.
83. Berstad A., Borkje B., Riedel B., Elsayed S. Increased fecal eosinophil cationic protein in inflammatory bowel disease. Hepatogastroenterology 1993, 40:276-278.
84. Carlson M., Raab Y., Peterson C., Hallgren R., Venge P. Increased intraluminal release of eosinophil granule proteins EPO, ECP, EPX, and cytokines in ulcerative colitis and proctitis in segmental perfusion. Am J Gastroenterol 1999, 94:1876-1883.
85. Luck W., Becker M., Niggemann B., Wahn U. In vitro release of eosinophil cationic protein from peripheral eosinophils reflects disease activity in childhood Crohn disease and ulcerative colitis. Eur J Pediatr 1997, 156:921-924.
86. Wedemeyer J., Vosskuhl K. Role of gastrointestinal eosinophils in inflammatory bowel disease and intestinal tumours. Best Pract Res Clin Gastroenterol 2008, 22:537-549.
87. Madara J.L., Podolsky D.K., King N.W., Sehgal P.K., Moore R., Winter H.S. Characterization of spontaneous colitis in cotton-top tamarins (Saguinus oedipus) and its response to sulfasalazine. Gastroenterology 1985, 88:13-19.
88. Sundberg J.P., Elson C.O., Bedigian H., Birkenmeier E.H. Spontaneous, heritable colitis in a new substrain of C3H/HeJ mice. Gastroenterology 1994, 107:1726-1735.
89. Matsumoto S., Okabe Y., Setoyama H., Takayama K., Ohtsuka J., Funahashi H., et al. Inflammatory bowel disease-like enteritis and caecitis in a senescence accelerated mouse P1/Yit strain. Gut 1998, 43:71-78.
90. McNamee E.N., Wermers J.D., Masterson J.C., Collins C.B., Lebsack M.D., Fillon S., et al. Novel model of T(H)2-polarized chronic ileitis: The SAMP1 mouse. Inflamm Bowel Dis 2009.
91. Rivera-Nieves J., Bamias G., Vidrich A., Marini M., Pizarro T.T., McDuffie M.J., et al. Emergence of perianal fistulizing disease in the SAMP1/YitFc mouse, a spontaneous model of chronic ileitis. Gastroenterology 2003, 124:972-982.
92. Takeda T., Hosokawa M., Takeshita S., Irino M., Higuchi K., Matsushita T., et al. A new murine model of accelerated senescence. Mech Ageing Dev 1981, 17:183-194.
93. Lodes M.J., Cong Y., Elson C.O., Mohamath R., Landers C.J., Targan S.R., et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 2004, 113:1296-1306.
94. Olson T.S., Reuter B.K., Scott K.G., Morris M.A., Wang X.M., Hancock L.N., et al. The primary defect in experimental ileitis originates from a nonhematopoietic source. J Exp Med 2006, 203:541-552.
95. Takedatsu H., Mitsuyama K., Matsumoto S., Handa K., Suzuki A., Funabashi H., et al. Interleukin-5 participates in the pathogenesis of ileitis in SAMP1/Yit mice. Eur J Immunol 2004, 34:1561-1569.
96. Masterson J.C., McNamee E.N., Jedlicka P., et al. CCR3 Blockade Attenuates Eosinophilic Ileitis and Associated Remodeling. Am J Pathol 2011, 179:2302-2314.
97. Morris G.P., Beck P.L., Herridge M.S., Depew W.T., Szewczuk M.R., Wallace J.L. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989, 96:795-803.
98. Boirivant M., Fuss I.J., Chu A., Strober W. Oxazolone colitis: A murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J Exp Med 1998, 188:1929-1939.
99. Dieleman L.A., Elson C.O., Tennyson G.S., Beagley K.W. Kinetics of cytokine expression during healing of acute colitis in mice. Am J Physiol 1996, 271:G130-G136.
100. Forbes E., Murase T., Yang M., Matthaei K.I., Lee J.J., Lee N.A., et al. Immunopathogenesis of experimental ulcerative colitis is mediated by eosinophil peroxidase. J Immunol 2004, 172:5664-5675.
101. Stevceva L., Pavli P., Husband A., Matthaei K.I., Young I.G., Doe W.F. Eosinophilia is attenuated in experimental colitis induced in IL-5 deficient mice. Genes Immun 2000, 1:213-218.
102. Ahrens R., Waddell A., Seidu L., Blanchard C., Carey R., Forbes E., et al. Intestinal macrophage/epithelial cell-derived CCL11/eotaxin-1 mediates eosinophil recruitment and function in pediatric ulcerative colitis. J Immunol 2008, 181:7390-7399.
103. Vieira A.T., Fagundes C.T., Alessandri A.L., Castor M.G., Guabiraba R., Borges V.O., et al. Treatment with a novel chemokine-binding protein or eosinophil lineage-ablation protects mice from experimental colitis. Am J Pathol 2009, 175:2382-2391.
104. Artis D., Humphreys N.E., Potten C.S., Wagner N., Muller W., McDermott J.R., et al. Beta7 integrin-deficient mice: delayed leukocyte recruitment and attenuated protective immunity in the small intestine during enteric helminth infection. Eur J Immunol 2000, 30:1656-1664.
105. Brandt E.B., Zimmermann N., Muntel E.E., Yamada Y., Pope S.M., Mishra A., et al. The alpha4bbeta7-integrin is dynamically expressed on murine eosinophils and involved in eosinophil trafficking to the intestine. Clin Exp Allergy 2006, 36:543-553.
106. Mishra A., Hogan S.P., Brandt E.B., Wagner N., Crossman M.W., Foster P.S., et al. Enterocyte expression of the eotaxin and interleukin-5 transgenes induces compartmentalized dysregulation of eosinophil trafficking. J Biol Chem 2002, 277:4406-4412.
107. Bruewer M., Luegering A., Kucharzik T., Parkos C.A., Madara J.L., Hopkins A.M., et al. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol 2003, 171:6164-6172.
108. Furuta G.T., Turner J.R., Taylor C.T., Hershberg R.M., Comerford K., Narravula S., et al. Hypoxia-inducible factor 1-dependent induction of intestinal trefoil factor protects barrier function during hypoxia. J Exp Med 2001, 193:1027-1034.
109. Mashimo H., Wu D.C., Podolsky D.K., Fishman M.C. Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science 1996, 274:262-265.
110. Vandenbroucke K., Hans W., Van Huysse J., Neirynck S., Demetter P., Remaut E., et al. Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology 2004, 127:502-513.
111. Hermiston M.L., Gordon J.I. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science 1995, 270:1203-1207.
112. Panwala C.M., Jones J.C., Viney J.L. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol 1998, 161:5733-5744.
113. -/- colitis. Inflamm Res 2007, 56:439-446.
114. Shull M.M., Ormsby I., Kier A.B., Pawlowski S., Diebold R.J., Yin M., et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992, 359:693-699.
115. Smythies L.E., Sellers M., Clements R.H., Mosteller-Barnum M., Meng G., Benjamin W.H., et al. Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J Clin Invest 2005, 115:66-75.
116. Gorelik L., Flavell R.A. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 2000, 12:171-181.
117. Kuhn R., Lohler J., Rennick D., Rajewsky K., Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993, 75:263-274.
118. Specht S., Arriens S., Hoerauf A. Induction of chronic colitis in IL-10 deficient mice requires IL-4. Microbes Infect 2006, 8:694-703.
119. Ostanin D.V., Bao J., Koboziev I., Gray L., Robinson-Jackson S.A., Kosloski-Davidson M., et al. T cell transfer model of chronic colitis: concepts, considerations, and tricks of the trade. Am J Physiol Gastrointest Liver Physiol 2009, 296:G135-G146.
120. Fort M., Lesley R., Davidson N., Menon S., Brombacher F., Leach M., et al. IL-4 exacerbates disease in a Th1 cell transfer model of colitis. J Immunol 2001, 166:2793-2800.
121. Woods R.K., Abramson M.J., Bailey H., Walter EH International prevalences of reported food allergies and intolerances. Comparisons arising from the European Community Respiratory Health Survey (ECRHS). Eur J Clin Nutr 2001, 55:298-304.
122. Sicherer S.H., Munoz-Furlong A., Sampson H.A. Prevalence of seafood allergy in the United States determined by a random telephone survey. J Allergy Clin Immunol 2004, 114:159-165.
123. Sampson H.A. Food Allergy. J Allergy Clin Immunol 2003, 111:S540-S547.
124. Sampson H.A. Update on food allergy. J Allergy Clin Immunol 2004, 113:805-819.
125. Munoz-Furlong A., Sampson H.A., Sicherer S.H. Prevalence of self-reported seafood allergy in the US. [abstract]. J Allergy Clin Immunol 2004, 113(Suppl.):S100.
126. Torpier G., Colombel J.F., Mathieu-Chandelier C., Capron M., Dessaint J.P., Cortot A., et al. Eosinophilic gastroenteritis: ultrastructural evidence for a selective release of eosinophil major basic protein. Clin Exp Immunol 1988, 74:404-408.
127. Machida H.M., Catto S.A., Gall D.G., Trevenen C., Scott R.B. Allergic colitis in infancy: clinical and pathologic aspects [see comments]. J Pediatr Gastroenterol Nutr 1994, 19:22-26.
128. Bischoff S.C., Grabowsky M.S., Manns M.P. Quantification of inflammatory mediators in stool samples of patients with inflammatory bowel disorders and controls. Dig Dis Sci 1997, 42:394-403.
129. Bischoff S.C., Mayer J., Nguyen Q.T., Stolte M., Manns M.P. Immunohistological assessment of intestinal eosinophil activation in patients with eosinophilic gastroenteritis and inflammatory bowel disease. Am J Gastroenterol 1999, 94:3521-3529.
130. Schwab D., Raithel M., Klein P., Winterkamp S., Weidenhiller M., Radespiel-Troeger M., et al. Immunoglobulin E and eosinophilic cationic protein in segmental lavage fluid of the small and large bowel identify patients with food allergy. Am J Gastroenterol 2001, 96:508-514.
131. Talley N.J., Kephart G.M., McGovern T.W., Carpenter H.A., Gleich G.J. Deposition of eosinophil granule major basic protein in eosinophilic gastroenteritis and celiac disease. Gastroenterology 1992, 103:137-145.
132. Spry C.J., Tai P.C., Barkans J. Tissue localization of human eosinophil cationic proteins in allergic diseases. Int Arch Allergy Appl Immunol 1985, 77:252-254.
133. Klein N.C., Hargrove R.L., Sleisenger M.H., Jeffries G.H. Eosinophilic gastroenteritis. Medicine 1970, 2:215-225.
134. Cello J.P. Eosinophilic gastroenteritis: A complex disease entity. Am J Med 1979, 67:1097-1114.
135. Osterfeld H., Ahrens R., Strait R., Finkelman F.D., Renauld J.C., Hogan S.P. Differential roles for the IL-9/IL-9 receptor alpha-chain pathway in systemic and oral antigen-induced anaphylaxis. J Allergy Clin Immunol 2010, 125:469-476. e2.
136. Brandt E.B., Strait R.T., Wang Q., Hersko D., Muntel E., Finkelman F.D., et al. Oral antigen-induced intestinal anaphylaxis requires IgE-dependent mast cell degranulation. J Allergy Clin Immunol 2003, 111:S33919. Song, D. J., Cho, J. Y., Miller, M., Strangman, W., Zhang, M., Varki, A. and Broide, D. H. (2009) Anti-Siglec-F antibody inhibits oral egg allergen induced intestinal eosinophilic inflammation in a mouse model. Clin Immunol. 131, 157-169.
137. Finkelman F.D. Anaphylaxis: lessons from mouse models. J Allergy Clin Immunol 2007, 120:506-515.
138. Piliponsky A., Gleich G., Bar I., Levi-Schaffer F. Effects of eosinophils on mast cells: a new pathway for the perpetuation of allergic inflammation. Mol Immunol 2002, 38:1369.
139. Zheutlin L.M., Ackerman S.J., Gleich G.J., Thomas L.L. Stimulation of basophil and rat mast cell histamine release by eosinophil granule-derived cationic proteins. Source (Bibliographic Citation): J Immunol 1984, 133:2180-2185.
140. Brandt E.B., Strait R.T., Hershko D., Wang Q., Muntel E.E., Scribner T.A., et al. Mast cells are required for experimental oral allergen-induced diarrhea. J Clin Invest 2003, 112:1666-1677.
141. Song D.J., Cho J.Y., Miller M., Strangman W., Zhang M., Varki A., et al. Anti-Siglec-F antibody inhibits oral egg allergen induced intestinal eosinophilic inflammation in a mouse model. Clin Immunol 2009, 131:157-169.
142. Zhang J.Q., Biedermann B., Nitschke L., Crocker P.R. The murine inhibitory receptor mSiglec-E is expressed broadly on cells of the innate immune system whereas mSiglec-F is restricted to eosinophils. Eur J Immunol 2004, 34:1175-1184.
143. Yokoi H., Choi O.H., Hubbard W., Lee H.S., Canning B.J., Lee H.H., et al. Inhibition of FcepsilonRI-dependent mediator release and calcium flux from human mast cells by sialic acid-binding immunoglobulin-like lectin 8 engagement. J Allergy Clin Immunol 2008, 121:499-505 e1.
144. Yokoi H., Myers A., Matsumoto K., Crocker P.R., Saito H., Bochner B.S. Alteration and acquisition of Siglecs during in vitro maturation of CD34+ progenitors into human mast cells. Allergy 2006, 61:769-776.
145. Hogan S.P., Mishra A., Brandt E.B., Foster P.S., Rothenberg M.E. A critical role for eotaxin in experimental oral antigen-induced eosinophilic gastrointestinal allergy. Proc Natl Acad Sci USA 2000, 97:6681-6686.
146. Hogan S.P., Mishra A., Brandt E.B., Royalty M.P., Pope S.M., Zimmermann N., et al. A pathological function for eotaxin and eosinophils in eosinophilic gastrointestinal inflammation. Nat Immunol 2001, 2:353-360.
147. Kelly K.J. Eosinophilic gastroenteritis. J Pediatr Gastroenterol Nutr 2000, 30(Suppl):S28-S35.
148. Dvorak A.M., Onderdonk A.B., McLeod R.S., Monahan-Earley R.A., Antonioli D.A., Cullen J., et al. Ultrastructural identification of exocytosis of granules from human gut eosinophils in vivo. Int Arch Allergy Immunol 1993, 102:33-45.
149. Sampson H.A. Food allergy. Part 1: immunopathogenesis and clinical disorders. J Allergy Clin Immunol 1999, 103:717-728.
150. Mishra A., Hogan S.P., Brandt E.B., Wagner N., Crossman M.W., Foster P.S., et al. Enterocyte expression of the eotaxin and interleukin-5 transgenes induces compartmentalized dysregulation of eosinophil trafficking. J Biol Chem 2002, 277:4406-4412.
151. Bain B., Pierre R., Imbert M., Vardiman J.W., Brunning R.D., Flandrin G. Chronic eosinophilic leukaemia and the hypereosinophilic syndrome. World Health Organization of Tumours: Tumours of Haematopoietic and Lymphoid Tissues 2001, IARC Press, Lyon, France. E.S. Jaffe, N. Harris, H. Stein, J.W. Vardiman (Eds.).
152. Chusid M.J., Dale D.C., West B.C., Wolff S.M. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975, 54:1-27.
153. Cools J., DeAngelo D.J., Gotlib J., Stover E.H., Legare R.D., Cortes J., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003, 348:1201-1214.
154. Bacher U., Reiter A., Haferlach T., Mueller L., Schnittger S., Kern W., et al. A combination of cytomorphology, cytogenetic analysis, fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction for establishing clonality in cases of persisting hypereosinophilia. Haematologica 2006, 91:817-820.
155. Klion A.D., Noel P., Akin C., Law M.A., Gilliland D.G., Cools J., et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003, 101:4660-4666.
156. La Starza R., Specchia G., Cuneo A., Beacci D., Nozzoli C., Luciano L., et al. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases. Haematologica 2005, 90:596-601.
157. Ogbogu P.U., Bochner B.S., Butterfield J.H., Gleich G.J., Huss-Marp J., Kahn J.E., et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 2009, 124:1319-1325. e3.
158. Pardanani A., Ketterling R.P., Li C.Y., Patnaik M.M., Wolanskyj A.P., Elliott M.A., et al. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res 2006, 30:965-970.
159. Roche-Lestienne C., Lepers S., Soenen-Cornu V., Kahn J.E., Lai J.L., Hachulla E., et al. Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Leukemia 2005, 19:792-798.
160. Score J., Curtis C., Waghorn K., Stalder M., Jotterand M., Grand F.H., et al. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia 2006, 20:827-832.
161. Vandenberghe P., Wlodarska I., Michaux L., Zachee P., Boogaerts M., Vanstraelen D., et al. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia 2004, 18:734-742.
162. Baxter E.J., Hochhaus A., Bolufer P., Reiter A., Fernandez J.M., Senent L., et al. The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Hum Mol Genet 2002, 11:1391-1397.
163. Curtis C.E., Grand F.H., Musto P., Clark A., Murphy J., Perla G., et al. Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia. Br J Haematol 2007, 138:77-81.
164. Trempat P., Villalva C., Laurent G., Armstrong F., Delsol G., Dastugue N., et al. Chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor alpha receptor: a new clinical target for STI571/Glivec. Oncogene 2003, 22:5702-5706.
165. Walz C., Curtis C., Schnittger S., Schultheis B., Metzgeroth G., Schoch C., et al. Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene. Genes Chromosomes Cancer 2006, 45:950-956.
166. Tefferi A., Vardiman J.W. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008, 22:14-22.
167. Bain B.J., Gilliland D.G., Horny H.-P., Vardiman J.W., Swerdlow S.H., Campo E., et al. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB and FGFR1. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissue 2008, IARC Press, Lyon, France.
168. Agerstam H., Jaras M., Andersson A., Johnels P., Hansen N., Lassen C., et al. Modeling the human 8p11-myeloproliferative syndrome in immunodeficient mice. Blood 2010, 116:2103-2111.
169. Yamada Y., Rothenberg M.E., Lee A.W., Akei H.S., Brandt E.B., Williams D.A., et al. The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease. Blood 2006, 107:4071-4079.
170. Roumiantsev S., Krause D.S., Neumann C.A., Dimitri C.A., Asiedu F., Cross N.C., et al. Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. Cancer Cell 2004, 5:287-298.
171. Golub T.R., Barker G.F., Lovett M., Gilliland D.G. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994, 77:307-316.
172. Cools J., Stover E.H., Boulton C.L., Gotlib J., Legare R.D., Amaral S.M., et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease. Cancer Cell 2003, 3:459-469.
173. Bank I., Amariglio N., Reshef A., Hardan I., Confino Y., Trau H., et al. The hypereosinophilic syndrome associated with CD4+CD3- helper type 2 (Th2) lymphocytes. Leuk Lymphoma 2001, 42:123-133.
174. Tefferi A., Pardanani A. Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis. Int J Hematol 2004, 79:441-447.
175. Tefferi A., Lasho T.L., Brockman S.R., Elliott M.A., Dispenzieri A., Pardanani A. FIP1L1-PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia. Haematologica 2004, 89:871-873.
176. Robyn J., Lemery S., McCoy J.P., Kubofcik J., Kim Y.J., Pack S., et al. Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA-positive hypereosinophilic syndrome. Br J Haematol 2006, 132:286-292.
177. Dent L.A., Strath M., Mellor A.L., Sanderson C.J. Eosinophilia in transgenic mice expressing interleukin 5. J Exp Med 1990, 172:1425-1431.
178. Rothenberg M.E., Klion A.D., Roufosse F.E., Kahn J.E., Weller P.F., Simon H.U., et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008, 358:1215-1228.
179. Gotlib V., Darji J., Bloomfield K., Chadburn A., Patel A., Braunschweig I. Eosinophilic variant of chronic myeloid leukemia with vascular complications. Leuk Lymphoma 2003, 44:1609-1613.
180. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H., et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol 1994, 87:746-754.
181. Brito-Babapulle F. Clonal eosinophilic disorders and the hypereosinophilic syndrome. Blood Rev 1997, 11:129-145.
182. Patnaik M.M., Rindos M., Kouides P.A., Tefferi A., Pardanani A. Systemic mastocytosis: a concise clinical and laboratory review. Arch Pathol Lab Med 2007, 131:784-791.
183. Pardanani A., Reeder T., Li C.Y., Tefferi A. Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia. Leuk Res 2003, 27:883-885.
184. Maric I., Robyn J., Metcalfe D.D., Fay M.P., Carter M., Wilson T., et al. KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. J Allergy Clin Immunol 2007, 120:680-687.
185. Lawrence J.B., Friedman B.S., Travis W.D., Chinchilli V.M., Metcalfe D.D., Gralnick H.R. Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis. Am J Med 1991, 91:612-624.
186. Yamada Y., Sanchez-Aguilera A., Brandt E.B., McBride M., Al-Moamen N.J., Finkelman F.D., et al. FIP1L1/PDGFRalpha synergizes with SCF to induce systemic mastocytosis in a murine model of chronic eosinophilic leukemia/hypereosinophilic syndrome. Blood 2008, 112:2500-2507.
187. von Bubnoff N., Gorantla S.P., Thone S., Peschel C., Duyster J. The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib). Blood 2006, 107:4970-4971. author reply 4972.
188. Ohnishi H., Kandabashi K., Maeda Y., Kawamura M., Watanabe T. Chronic eosinophilic leukaemia with FIP1L1-PDGFRA fusion and T674I mutation that evolved from Langerhans cell histiocytosis with eosinophilia after chemotherapy. Br J Haematol 2006, 134(5):547-549.
189. Stein M.L., Villanueva J.M., Buckmeier B.K., Yamada Y., Filipovich A.H., Assa'ad A.H., et al. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. J Allergy Clin Immunol 2008, 121:1473-1483. 1483 e1-4.
190. Zimmermann N., McBride M.L., Yamada Y., Hudson S.A., Jones C., Cromie K.D., et al. Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils. Allergy 2008, 63:1156-1163.
191. Aizawa H., Zimmermann N., Carrigan P.E., Lee J.J., Rothenberg M.E., Bochner B.S. Molecular analysis of human Siglec-8 orthologs relevant to mouse eosinophils: identification of mouse orthologs of Siglec-5 (mSiglec-F) and Siglec-10 (mSiglec-G). Genomics 2003, 82:521-530.
192. Zhang J.Q., Biedermann B., Nitschke L., Crocker P.R. The murine inhibitory receptor mSiglec-E is expressed broadly on cells of the innate immune system whereas mSiglec-F is restricted to eosinophils. Eur J Immunol 2004, 34:1175-1184.
193. Zhang M., Angata T., Cho J.Y., Miller M., Broide D.H., Varki A. Defining the in vivo function of Siglec-F, a CD33-related Siglec expressed on mouse eosinophils. Blood 2007, 109:4280-4287.
194. Nutku E., Aizawa H., Hudson S.A., Bochner B.S. Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. Blood 2003, 101:5014-5020.
195. Pardanani A., Tefferi A. Primary eosinophilic disorders: a concise review. Curr Hematol Malig Rep 2008, 3:37-43.
196. Magnusson M.K., Meade K.E., Brown K.E., Arthur D.C., Krueger L.A., Barrett A.J., et al. Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia. Blood 2001, 98:2518-2525.
197. Jackson C.C., Medeiros L.J., Miranda R.N. 8p11 myeloproliferative syndrome: a review. Hum Pathol 2010, 41:461-476.
198. Ostrander E.A., Galibert F., Patterson D.F. Canine genetics comes of age. Trends Genet 2000, 16:117-124.
199. Rowell J.L., McCarthy D.O., Alvarez C.E. Dog models of naturally occurring cancer. Trends Mol Med 2011, 17:380-388.
200. McEwen B.J. Eosinophils: a review. Vet Res Commun 1992, 16:11-44.
201. Iazbik M.C., Couto C.G. Morphologic characterization of specific granules in Greyhound eosinophils. Vet Clin Pathol 2005, 34:140-143.
202. Casal A.B., Freire F., Bautista-Harris G., Arencibia A., Oros J. Ultrastructural characteristics of blood cells of juvenile loggerhead sea turtles (Caretta caretta). Anat Histol Embryol 2007, 36:332-335.
203. Lilliehook I., Tvedten H. Investigation of hypereosinophilia and potential treatments. Vet Clin North Am Small Anim Pract 2003, 33:1359-1378. viii.
204. Lilliehook I., Gunnarsson L., Zakrisson G., Tvedten H. Diseases associated with pronounced eosinophilia: a study of 105 dogs in Sweden. J Small Anim Pract 2000, 41:248-253.
205. Matsumoto K., Matsushita N., Tomozawa H., Tagawa Y. Hematological characteristics of rats spontaneously developing eosinophilia. Exp Anim 2000, 49:211-215.
206. Muto S., Hayashi M., Matsushita N., Momose Y., Shibata N., Umemura T., et al. Systemic and eosinophilic lesions in rats with spontaneous eosinophilia (mes rats). Vet Pathol 2001, 38:346-350.
207. Mori M., Li G., Hashimoto M., Nishio A., Tomozawa H., Suzuki N., et al. Pivotal Advance: Eosinophilia in the MES rat strain is caused by a loss-of-function mutation in the gene for cytochrome b(-245), alpha polypeptide (Cyba). J Leukoc Biol 2009, 86:473-478.
208. Hoenerhoff M.J., Starost M.F., Ward J.M. Eosinophilic crystalline pneumonia as a major cause of death in 129S4/SvJae mice. Vet Pathol 2006, 43:682-688.
209. Windsor R.C., Sturges B.K., Vernau K.M., Vernau W. Cerebrospinal fluid eosinophilia in dogs. J Vet Intern Med 2009, 23:275-281.
210. Heidemann S.M., Fiore M., Sood S., Ham S. Eosinophil activation in the cerebrospinal fluid of children with shunt obstruction. Pediatr Neurosurg 2010, 46:255-258.
211. Lo Re V., Gluckman S.J. Eosinophilic meningitis. Am J Med 2003, 114:217-223.
212. Mazzei M.J., Bissett S.A., Murphy K.M., Hunter S., Neel J.A. Eosinophilic esophagitis in a dog. J Am Vet Med Assoc 2009, 235:61-65.
213. German A.J., Hall E.J., Day M.J. Analysis of leucocyte subsets in the canine intestine. J Comp Pathol 1999, 120:129-145.
214. Waly N., Gruffydd-Jones T.J., Stokes C.R., Day M.J. The distribution of leucocyte subsets in the small intestine of healthy cats. J Comp Pathol 2001, 124:172-182.
215. Packer M., Patterson-Kane J.C., Smith K.C., Durham A.E. Quantification of immune cell populations in the lamina propria of equine jejunal biopsy specimens. J Comp Pathol 2005, 132:90-95.
216. Sihvo H.K., Simola O.T., Vainionpaa M.H., Syrja P.E. Pathology in practice. Severe chronic multifocal intramural fibrosing and eosinophilic enteritis, with occasional intralesional bacteria, consistent with feline gastrointestinal eosinophilic sclerosing fibroplasia. (FIESF). J Am Vet Med Assoc 2011, 238:585-587.
217. Craig L.E., Hardam E.E., Hertzke D.M., Flatland B., Rohrbach B.W., Moore R.R. Feline gastrointestinal eosinophilic sclerosing fibroplasia. Vet Pathol 2009, 46:63-70.
218. Lyles S.E., Panciera D.L., Saunders G.K., Leib M.S. Idiopathic eosinophilic masses of the gastrointestinal tract in dogs. J Vet Intern Med 2009, 23:818-823.
219. Schumacher J., Edwards J.F., Cohen N.D. Chronic idiopathic inflammatory bowel diseases of the horse. J Vet Intern Med 2000, 14:258-265.
220. Kleinschmidt S., Meneses F., Nolte I., Hewicker-Trautwein M. Characterization of mast cell numbers and subtypes in biopsies from the gastrointestinal tract of dogs with lymphocytic-plasmacytic or eosinophilic gastroenterocolitis. Vet Immunol Immunopathol 2007, 120:80-92.
221. Craven M., Simpson J.W., Ridyard A.E., Chandler M.L. Canine inflammatory bowel disease: retrospective analysis of diagnosis and outcome in 80 cases (1995-2002). J Small Anim Pract 2004, 45:336-342.
222. Archer D.C., Barrie Edwards G., Kelly D.F., French N.P., Proudman C.J. Obstruction of equine small intestine associated with focal idiopathic eosinophilic enteritis: an emerging disease?. Vet J 2006, 171:504-512.
223. Swain J.M., Licka T., Rhind S.M., Hudson N.P. Multifocal eosinophilic enteritis associated with a small intestinal obstruction in a standardbred horse. Vet Rec 2003, 152:648-651.
224. Bedenice D., Mazan M.R., Hoffman A.M. Association between cough and cytology of bronchoalveolar lavage fluid and pulmonary function in horses diagnosed with inflammatory airway disease. J Vet Intern Med 2008, 22:1022-1028.
225. Couetil L.L., Rosenthal F.S., DeNicola D.B., Chilcoat C.D. Clinical signs, evaluation of bronchoalveolar lavage fluid, and assessment of pulmonary function in horses with inflammatory respiratory disease. Am J Vet Res 2001, 62:538-546.
226. Venema C.M., Patterson C.C. Feline asthma: what's new and where might clinical practice be heading?. J Feline Med Surg 2010, 12:681-692.
227. Clercx C., Peeters D. Canine eosinophilic bronchopneumopathy. Vet Clin North Am Small Anim Pract 2007, 37:917-935. vi.
228. Clercx C., Peeters D., German A.J., Khelil Y., McEntee K., Vanderplasschen A., et al. An immunologic investigation of canine eosinophilic bronchopneumopathy. J Vet Intern Med 2002, 16:229-237.
229. Peeters D., Day M.J., Clercx C. Distribution of leucocyte subsets in bronchial mucosa from dogs with eosinophilic bronchopneumopathy. J Comp Pathol 2005, 133:128-135.
230. Barrs V.R., Beatty J.A., McCandlish I.A., Kipar A. Hypereosinophilic paraneoplastic syndrome in a cat with intestinal T cell lymphosarcoma. J Small Anim Pract 2002, 43:401-405.
231. Marchetti V., Benetti C., Citi S., Taccini V. Paraneoplastic hypereosinophilia in a dog with intestinal T-cell lymphoma. Vet Clin Pathol 2005, 34:259-263.
232. La Perle K.M., Piercy R.J., Long J.F., Blomme E.A. Multisystemic, eosinophilic, epitheliotropic disease with intestinal lymphosarcoma in a horse. Vet Pathol 1998, 35:144-146.